2013-20415. Proposed Collection; 60-day Comment Request: NIH NCI Central Institutional Review Board (CIRB) Initiative (NCI)
-
Start Preamble
SUMMARY:
In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the National Cancer Institute (NCI), National Institutes of Health (NIH), will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.
To Submit Comments and for Further Information: To obtain a copy of the data collection plans and instruments, submit comments in writing, or request more information on the proposed project, contact: CAPT Michael Montello, Pharm. D., MBA, Cancer Therapy Evaluation Program, Operations and Informatics Branch, 9609 Medical Center Drive, Rockville, MD 20850 or call non-toll-free number (240) 276-6080 or Email your request, including your address to: mike.montello@nih.gov. Formal requests for additional plans and instruments must be requested in writing.
Comment Due Date: Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication.
Proposed Collection: NIH NCI Central Institutional Review Board (CIRB) Initiative (NCI), 0925-0625, Revision, National Cancer Institute (NCI), National Institutes of Health (NIH).
Need and Use of Information Collection: The National Cancer Institute (NCI) Central Institutional Review Board (CIRB) provides a centralized approach to human subject protection and provides a cost efficient approach avoiding duplication of effort at each institution. The CIRB provides the services of a fully constituted IRB and provides a comprehensive and efficient mechanism to meet regulatory requirements pertaining to human subject protections including: Initial reviews, continuing reviews, review of amendments, and adverse events. The Initiative consists of three central IRBs: Adult CIRB—late phase emphasis, Adult CIRB—early phase emphasis, and Pediatric CIRB. CIRB membership includes oncology physicians, surgeons, nurses, patient advocates, ethicists, statisticians, pharmacists, attorneys and other health professionals. The benefits of the CIRB Initiative reaches research participants, investigators and research staff, Institutional Review Boards (IRB), and Institutions. Benefits include: Study participants having dedicated review of NCI-sponsored trials for participant protections, access to more trials more quickly and access to trials for rare diseases, accrual to trials begin more rapidly, ease of opening trials, elimination of need to submit study materials to local IRBs, and elimination of the need for a full board review. The benefits to the National Clinical Trials Network and Experimental Therapy-Clinical Trials Network include a cost efficient approach that avoids duplication of efforts at each institution. A variety of information collection tools are needed to support NCI's CIRB activities which include: Worksheets, forms and a survey that is provided to all customers contacting the CIRB helpdesk.
OMB approval is requested for 3 years. There are no costs to respondents other than their time. The total estimated annualized burden hours are 2,199.Start Printed Page 52205
Start SignatureEstimates of Annual Burden Hours
Form name Type of respondents Number of respondents Frequency of responses per respondent Average burden per response (in hours) Total annual burden hours CIRB Customer Satisfaction Survey Participants/Board Members 1500 1 10/60 250 Request for 30 Day Web site Access Form Participants 25 1 10/60 4 Authorization Agreement and Division of Responsibilities between the NCI CIRB and Signatory Institution Participants 340 1 30/60 170 NCI CIRB Signatory Enrollment Form Participants 40 1 4 160 IRB Staff at Signatory Institution's IRB Participants 25 1 10/60 4 Investigator at Signatory Institution Participants 65 1 10/60 11 Research Staff at Signatory Institution Participants 65 1 10/60 11 Investigator at Affiliate Institution with an IRB Participants 25 1 10/60 4 Research Staff at Affiliate Institution with an IRB Participants 25 1 10/60 4 Investigator at Affiliate Institution without an IRB Participants 25 1 10/60 4 Research Staff at Affiliate Institution without an IRB Participants 25 1 10/60 4 Institutional Contact for Signatory Institution Participants 65 1 10/60 11 IRB at Signatory Institution Participants 25 1 10/60 4 Component Institution at Signatory Institution Participants 65 1 10/60 11 IRB at Affiliate Institution Participants 25 1 10/60 4 Affiliate Institution without an IRB Participants 25 1 10/60 4 Facilitated Review Acceptance Form Participants 300 1 10/60 50 Study Review Responsibility Transfer Form Participants 80 1 10/60 13 Annual Signatory Institution Worksheet About Local Context Participants 120 1 20/60 40 Annual Principal Investigator Worksheet About Local Context Participants 120 1 20/60 40 Study-Specific Worksheet About Local Context Participants 220 1 20/60 73 Study Closure or Transfer of Study Review Responsibility Form Participants 120 1 10/60 20 Potential Unanticipated Problem or Serious or Continuing Noncompliance Reporting Form Participants 120 1 15/60 30 Add or Remove Signatory and/or Component Institution Personnel Participants 120 1 10/60 20 Add or Remove Affiliate Institution Personnel Participants 120 1 10/60 20 Add or Remove Component Institution Participants 120 1 10/60 20 Add or Remove Affiliate Institution Participants 120 1 10/60 20 One Time Study Roll Over Worksheet Participants 120 1 10/60 20 Change of Signatory Institution PI Form Participants 120 1 10/60 20 CIRB Board Member Biographical Sketch Form Board Members 25 1 15/60 6.25 CIRB Board Member Contact Information Form Board Members 25 1 10/60 4 CIRB Board Member W-9 Board Members 25 1 15/60 6 CIRB Board Member Non-Disclosure Agreement (NDA) Board Members 25 1 10/60 4 CIRB Direct Deposit Form Board Members 25 1 15/60 6 NCI Adult/Pediatric CIRB Application for Treatment Studies Participants 25 1 2 50 NCI Adult/Pediatric CIRB Application for Ancillary Studies Participants 10 1 2 20 NCI Adult/Pediatric CIRB Application for Continuing Review Participants 80 1 1 80 Summary of CIRB Application Revisions Participants 20 1 30/60 10 Locally-Developed Material Submission Form Participants 15 1 15/60 4 Application Request to Review Translated Documents Participants 15 1 15/60 4 Adult Initial Review of Cooperative Group Protocol Board Members 15 1 4 60 Pediatric Initial Review of Cooperative Group Protocol Board Members 15 1 4 60 Adult Continuing Review of Cooperative Group Protocol Board Members 130 1 1 130 Pediatric Continuing Review of Cooperative Group Protocol Board Members 70 1 1 70 Adult Amendment of Cooperative Group Protocol Board Members 10 1 2 20 Pediatric Amendment of Cooperative Group Protocol Board Members 10 1 2 20 Adult Cooperative Group Response to CIRB Review Participants 15 1 1 15 Pediatric Cooperative Group Response to CIRB Review Participants 10 1 1 10 Adult Pharmacist's Review of a Cooperative Group Study Board Members 10 1 2 20 Pediatric Pharmacist's Review of a Cooperative Group Study Board Members 20 1 2 40 CIRB Statistical Reviewer Form Board Members 30 1 30/60 15 Determination of Unanticipated Problem (UP) and/or Serious or Continuing Noncompliance (SCN) Board Members 40 1 10/60 7 Adult Expedited Amendment Review Board Members 350 1 30/60 175 Start Printed Page 52206 Ped Expedited Amendment Review Board Members 150 1 30/60 75 Adult Expedited Continuing Review Board Members 120 1 30/60 60 Ped Expedited Continuing Review Board Members 70 1 30/60 35 Adult Expedited Study Closure Board Members 20 1 20/60 7 Ped Expedited Study Closure Board Members 20 1 20/60 7 Adult Expedited Study Chair Response to Required Mod Board Members 350 1 15/60 88 Ped Expedited Study Chair Response to Required Mod Board Members 150 1 15/60 38 Reviewer Worksheet of Translated Documents Board Members 15 1 15/60 4 Reviewer Advertisement Checklist Board Members 10 1 20/60 3 Dated: August 15, 2013.
Vivian Horovitch-Kelley,
Program Analyst, National Institutes of Health.
[FR Doc. 2013-20415 Filed 8-21-13; 8:45 am]
BILLING CODE 4140-01-P
Document Information
- Published:
- 08/22/2013
- Department:
- National Institutes of Health
- Entry Type:
- Notice
- Document Number:
- 2013-20415
- Dates:
- Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication.
- Pages:
- 52204-52206 (3 pages)
- PDF File:
- 2013-20415.pdf
- Supporting Documents:
- » License Agreements; Start-Up Exclusive Evaluation Option: Activators of Human Pyruvate Kinase to Treat Cancer
- » Meetings: Eunice Kennedy Shriver National Institute of Child Health and Human Development
- » Meetings: National Institute of Nursing Research
- » Meetings: National Institute of Allergy and Infectious Diseases
- » Meetings: National Eye Institute
- » Meetings: Eunice Kennedy Shriver National Institute of Child Health and Human Development
- » Meetings: Center for Scientific Review
- » Meetings: Center for Scientific Review
- » Meetings: National Institute of Environmental Health Sciences
- » Meetings: National Human Genome Research Institute